Study to assess effect of device and formulation on Pharmacokinetics (PK) of AZD1402

Study identifier:D2912C00001

ClinicalTrials.gov identifier:NCT03921268

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized Open label, 3-period, 3-treatment, Crossover Study to Assess the Effect of Inhalation Device and Formulation on Pharmacokinetics Following a Single Inhaled Dose of AZD1402 in Healthy Subjects

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1402

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 25 Mar 2019
Primary Completion Date: 13 Jun 2019
Study Completion Date: 13 Jun 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria